- ISIN
- CH0329023102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 23, 2016
Highlights
- Market Cap
- $235.83M
- Enterprise Value
- $220.96M
- EPS (TTM)
- -$0.66
- Total Revenue (TTM)
- $3.70M
- Gross Profit (TTM)
- $3.70M
- EBITDA (TTM)
- -$64.45M
- Year Range
- $1.65 - $4.00
- Target Price
- $7.00
- ROA (TTM)
- -48.19%
- ROE (TTM)
- -210.00%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ACIU Performance Chart
AC Immune SA (ACIU) is down 23.9% since the beginning of the year. At $2 per share, ACIU is trading 40.2% below its 52-week high of $4. Investors who bought $1,000 worth of ACIU shares 5 years ago would now be looking at an investment worth $381.
Loading charts...
Returns By Period
AC Immune SA (ACIU) has returned -23.89% so far this year and 44.85% over the past 12 months.
AC Immune SA
- 1D
- -1.24%
- 1M
- -21.64%
- YTD
- -23.89%
- 6M
- -16.14%
- 1Y
- 44.85%
- 3Y*
- 0.56%
- 5Y*
- -17.57%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
ACIU Monthly Returns History
Based on dividend-adjusted daily data since Sep 23, 2016, ACIU's average daily return is +0.05%, while the average monthly return is +0.05%. At this rate, an investment would double in approximately 115.6 years.
Historically, 47% of months were positive and 53% were negative. The best month was May 2024 with a return of +87.5%, while the worst month was Jan 2019 at -56.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, ACIU closed higher 46% of trading days. The best single day was Jun 27, 2023 with a return of +71.7%, while the worst single day was Jan 30, 2019 at -66.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.59% | -8.15% | -6.14% | 10.18% | -12.21% | -10.15% | -23.89% | ||||||
| 2025 | 1.85% | -7.64% | -26.38% | -7.49% | -1.16% | 18.71% | 6.40% | -5.56% | 41.67% | 16.96% | -11.54% | 5.02% | 16.30% |
| 2024 | -35.80% | 12.77% | -18.23% | -16.22% | 87.50% | -14.19% | 2.51% | -21.03% | 17.03% | -24.87% | 19.72% | -20.59% | -46.00% |
| 2023 | 21.57% | -7.66% | 2.18% | -17.09% | 12.37% | 35.55% | 1.52% | 8.33% | -12.31% | 5.26% | 10.33% | 51.06% | 145.10% |
| 2022 | -10.71% | -7.92% | -1.72% | -10.50% | -12.29% | 14.97% | -2.49% | -14.20% | 4.64% | -13.61% | -6.59% | -20.00% | -58.79% |
| 2021 | 15.67% | 26.92% | 0.26% | -11.17% | -9.91% | 30.21% | -8.20% | 11.68% | -17.47% | -4.02% | -20.34% | -3.51% | -4.26% |
Benchmark Metrics
AC Immune SA has an annualized alpha of -0.70%, beta of 0.96, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since September 26, 2016.
- This stock participated in 180.25% of S&P 500 Index downside but only 60.86% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.70%
- Beta
- 0.96
- R²
- 0.05
- Upside Capture
- 60.86%
- Downside Capture
- 180.25%
Return for Risk
Risk / Return Rank
ACIU ranks 62 for risk / return — better than 62% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for AC Immune SA (ACIU) and compare them to S&P 500 Index.
| ACIU | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.57 | 2.24 | -1.67 |
Sortino ratioReturn per unit of downside risk | 1.43 | 3.07 | -1.64 |
Omega ratioGain probability vs. loss probability | 1.16 | 1.41 | -0.24 |
Calmar ratioReturn relative to maximum drawdown | 1.12 | 2.93 | -1.80 |
Martin ratioReturn relative to average drawdown | 2.21 | 13.52 | -11.31 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the AC Immune SA. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AC Immune SA was 92.33%, occurring on Apr 10, 2025. The portfolio has not yet recovered.
The current AC Immune SA drawdown is 87.62%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -92.33%Apr 2025 | 8y 6mo | — | 9y 8moSep 2016 - now |
Drawdown Indicators
| ACIU | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.33% | -56.78% | -35.55% |
Max Drawdown (1Y)Largest decline over 1 year | -40.10% | -9.10% | -31.00% |
Max Drawdown (3Y)Largest decline over 3 years | -70.40% | -18.90% | -51.50% |
Max Drawdown (5Y)Largest decline over 5 years | -82.32% | -25.43% | -56.89% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.62% | -0.74% | -86.88% |
Average DrawdownAverage peak-to-trough decline | -69.38% | -10.72% | -58.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.36% | 1.97% | +18.39% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AC Immune SA over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how AC Immune SA is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ACIU relative to other companies in the Biotechnology industry. Currently, ACIU has a P/S ratio of 64.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ACIU in comparison with other companies in the Biotechnology industry. Currently, ACIU has a P/B value of 7.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ACIU
Add AC Immune SA to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ACIU